Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
boston blog main
boston top stories
4
×
inclisiran
4
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
regeneron pharmaceuticals
cholesterol
clinical trials
new york
pcsk9
praluent
repatha
sanofi
alirocumab
alnylam pharmaceuticals
biotech
evolocumab
ldl
mt sinai hospital
pcsk9 inhibitors
prashant vaishnava
san francisco blog main
san francisco top stories
the medicines co.
boulder/denver blog main
boulder/denver top stories
cardiac
cardiovascular
cause of death
cedar-sinai
circulation
clinical studies
data
david maron
deals
detroit blog main
What
cholesterol
drug
4
×
lowering
medco
medicines
fda
new
twice
wave
aces
acquire
agreed
announced
big
billion
bringing
brings
cash
ceo
clears
closer
company
compound
deal
drugs
expensive
faces
filing
financial
flexible
foe
healthcare
hint
inched
inclisiran
inhibitors
key
known
market
meant
Language
unset
Current search:
inclisiran
×
drug
×
" boston top stories "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)